Lineage Cell Therapeutics (LCTX) Shares Outstanding (2010 - 2026)

Lineage Cell Therapeutics' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $249.3 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 9.17% year-over-year to $249.3 million; the TTM figure through Mar 2026 stood at $249.3 million (up 9.17% YoY), while the FY2025 annual figure was $243.1 million, up 10.3% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $249.3 million, up from $243.1 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $249.3 million in Q1 2026, with the low at $169647.0 in Q1 2022.
• The 5-year median for Shares Outstanding (Entity) is $188.8 million (2024), against an average of $186.5 million.
• Peak annual rise in Shares Outstanding (Entity) reached 104094.85% in 2022, while the deepest fall reached 99.9% in 2022.
• Lineage Cell Therapeutics' Shares Outstanding (Entity) stood at $170.1 million in 2022, then climbed by 2.88% to $175.0 million in 2023, then increased by 25.96% to $220.4 million in 2024, then climbed by 10.3% to $243.1 million in 2025, then grew by 2.54% to $249.3 million in 2026.
• Business Quant data shows LCTX's Shares Outstanding (Entity) at $249.3 million in Q1 2026, $243.1 million in Q4 2025, and $230.3 million in Q3 2025.